USANA Health Sciences reports Q1 results today with short sellers noticeably pulling back — a notable shift that runs counter to the broader defensive posturing visible in options markets.
Short interest has dropped sharply over the past two weeks. It fell from a recent peak near 2.9% of the float on April 21 to 2.6% by May 4, a decline of roughly 14% in short positions over that stretch. Borrow conditions remain relaxed — availability is extremely loose, with utilization barely above 0.5% against a 52-week high of 8.4%, meaning the lending pool is far from pressured. Cost to borrow, at 1.68%, is low and largely stable. The ORTEX short score of 39.4 ranks in the bottom 38th percentile of the universe — not a heavily shorted name by any measure.
Options tell a subtler story. The put/call ratio has actually eased in recent weeks, running at 1.02 — below its 20-day average of 1.17, and about one standard deviation lighter than that average. Through April, the PCR had been persistently elevated above 1.3, suggesting investors were hedging more aggressively then. The recent drop toward parity indicates that defensive positioning has unwound heading into the print, even as the stock itself has had a mixed few weeks: up 14% over the past month to $19.26, but slipping 1.3% on the week.
The bull case for USANA rests on valuation. The stock trades at around 15.7x trailing earnings and an EV/EBITDA of roughly 8x — modest multiples for a consumer health brand with a stable direct-selling model. The bear case is structural: the company operates heavily in Asia, particularly China, where macro headwinds and softening consumer demand have weighed on direct-sales businesses across the sector. Correlated peers tell a similarly mixed story — gained 2.8% on the day, rose nearly 4%, while slid 3.9% on the week. Analyst coverage has been thin and largely stale, with DA Davidson holding a Neutral rating and a target last set in early 2025 — well above the current price at $36, though that gap should be viewed cautiously given the stock's prolonged slide.
Ownership structure is one of the more distinctive features of USANA's setup. Founder Myron Wentz holds over 40% of shares outstanding, which concentrates voting power and limits the float available for active traders. Institutional holders including BlackRock, Vanguard, Pzena, and Renaissance Technologies each hold around 6% — a relatively fragmented institutional base that could amplify any post-earnings move in either direction.
The print will test whether USANA's China-exposed revenue base has stabilised enough to justify the stock's recovery from its March lows, or whether the recent bounce has run ahead of the underlying business.
See the live data behind this article on ORTEX.
Open USNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
